Improving the efficiency and quality of follow-up after curative treatment for breast cancer

ISRCTN ISRCTN74071417
DOI https://doi.org/10.1186/ISRCTN74071417
Secondary identifying numbers NTR121; 2
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
27/01/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr L J Boersma
Scientific

MAASTRO Clinic
Postbus 5800
Maastricht
6202 AZ
Netherlands

Study information

Study designRandomised, active controlled, factorial multicentre trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeQuality of life
Scientific title
Study acronymMaZorg studie/MaCare trial
Study objectives1. Regular physical follow-up can partly be replaced by nurse-led telephone follow-up, with at least similar Quality of Life (QoL), in breast cancer patients treated with curative intent (change in QoL less than five points)
2. An informative/educational group intervention (Info-Care-Programme) in the first three months of follow-up improves the QoL in breast cancer patients treated with curative intent (change in QoL more than ten points)
Ethics approval(s)Received from the local medical ethics committee
Health condition(s) or problem(s) studiedBreast cancer
InterventionThe first arm is the standard arm, and consists of usual follow-up as described in the regional guidelines. The patient has an appointment with the medical specialist and/or nurse-practitioner every three months during the first year, every six months during the second year, and thereafter once a year until at least five years. A mammography will be taken once a year, if needed supplemented by a breast ultrasound.

In arms two and four, where the effect of 'telephone follow-up' is studied, follow-up will consist of a first follow-up visit two to six weeks after treatment as usual, to evaluate the acute treatment related side effects. Thereafter, patients will only once a year be seen by either the medical oncologist/surgeon/Nurse-Practitioner (NP) or the radiation oncologist. This visit will be combined with the annual mammography. At the regular follow-up times (i.e. at three, six, nine, and 18 months), the NP will have a telephone interview with the patients. This telephone interview will be done by open discussion, and a semi structured questionnaire, including screening for physical and psychosocial symptoms, and compliance to hormonal therapy (if applicable). In addition, data about the side effects of treatment are collected during this telephone interview.

In the arms three and four, with an additional group intervention, the patients and their partners will follow the Info-Care Programme (ICP) led by two NPs, within three months of the end of the treatment. This programme, given at a central location in the region, consists of two interactive group sessions of about two to three hours of psycho-education, including mutual contact between participants for sharing. The ICP intervention is aimed at improving perceived behavioural control, and reduction of anxiety. To improve the feeling of self control and self reliance, information will be given about being alert to physical and psychosocial symptoms related to breast cancer and the (side) effects of the treatment. Information is given about the actions (e.g. call for professional help) that may be undertaken when symptoms occur, and about the scale of health care workers and interventions that are available. Discussions will also be conducted addressing issues such as how to deal with anxiety, mood changes, and changes in intimacy (i.e. altered feminity, body image, sexuality).
Intervention typeOther
Primary outcome measureCancer-specific QoL at 12 months after randomisation, measured by the global health status/QoL scale of the EORTC QLQ-C30.
Secondary outcome measures1. Other QoL scales, including breast cancer specific items, EuroQoL, perceived behavioural control, anxiety, and patients' satisfaction with follow-up
2. Costs will be determined based on standardised cost-diaries filled out by the patients over a predefined period, at the same time points.
3. The incidence of local recurrences and distant metastases, by whom these recurrences are detected, and whether they are detected with or without symptoms
Overall study start date01/06/2005
Completion date01/01/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants320
Key inclusion criteria1. Female patients with breast cancer without distant metastases
2. World Health Organisation (WHO) performance scale zero to two
3. No concomitant/previous malignant disease or psychiatric disorders
4. Treated with curative intent (i.e. lumpectomy or mastectomy, with or without radiotherapy and/or chemotherapy)
5. Treatment completed less than eight weeks prior to randomisation
6. Not included in another trial, requiring frequent follow-up
7. Able to read and speak fluently in Dutch
8. No medical diseases (treatment-related side-effects, concomitant tumours) requiring frequent follow-up
Key exclusion criteriaDoes not comply with the above inclusion criteria
Date of first enrolment01/06/2005
Date of final enrolment01/01/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

MAASTRO Clinic
Maastricht
6202 AZ
Netherlands

Sponsor information

Maastro Clinic (Netherlands)
Hospital/treatment centre

Department Radiotherapy
dr. Tanslaan 12
Maastricht
6229 ET
Netherlands

ROR logo "ROR" https://ror.org/059wkzj26

Funders

Funder type

Research organisation

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article study protocol 02/01/2007 Yes No
Results article results 07/02/2009 Yes No
Results article results 30/04/2010 Yes No
Results article economic evaluation results 01/05/2011 Yes No